CA3032858A1 - Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity - Google Patents

Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity Download PDF

Info

Publication number
CA3032858A1
CA3032858A1 CA3032858A CA3032858A CA3032858A1 CA 3032858 A1 CA3032858 A1 CA 3032858A1 CA 3032858 A CA3032858 A CA 3032858A CA 3032858 A CA3032858 A CA 3032858A CA 3032858 A1 CA3032858 A1 CA 3032858A1
Authority
CA
Canada
Prior art keywords
paracetamol
toxicity
pharmaceutically
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3032858A
Other languages
English (en)
French (fr)
Other versions
CA3032858C (en
Inventor
Boyd Eugene HALEY
Ragnar Axel Theodor KLINGBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emeramed Ltd
Original Assignee
Emeramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeramed Ltd filed Critical Emeramed Ltd
Publication of CA3032858A1 publication Critical patent/CA3032858A1/en
Application granted granted Critical
Publication of CA3032858C publication Critical patent/CA3032858C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3032858A 2016-08-05 2017-08-04 Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity Active CA3032858C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201613535 2016-08-05
GB1613535.2 2016-08-05
PCT/GB2017/052306 WO2018025049A1 (en) 2016-08-05 2017-08-04 New use of n,n-bis-2-mercaptoethyl isophthalamide

Publications (2)

Publication Number Publication Date
CA3032858A1 true CA3032858A1 (en) 2018-02-08
CA3032858C CA3032858C (en) 2025-09-23

Family

ID=

Also Published As

Publication number Publication date
MA45855B1 (fr) 2022-02-28
MA45855A (fr) 2021-03-17
EP4029497A1 (en) 2022-07-20
AU2017305661B2 (en) 2023-05-18
EA201990443A1 (ru) 2019-07-31
CY1125039T1 (el) 2023-03-24
EP3493849A1 (en) 2019-06-12
JP2019524782A (ja) 2019-09-05
PT3493849T (pt) 2022-02-23
ZA201900594B (en) 2019-08-28
RS62924B1 (sr) 2022-03-31
KR20190035724A (ko) 2019-04-03
LT3493849T (lt) 2022-03-10
MX2019000978A (es) 2019-06-10
KR102538388B1 (ko) 2023-05-30
IL264538B (en) 2022-10-01
US20250325503A1 (en) 2025-10-23
PL3493849T3 (pl) 2022-03-28
US20190240173A1 (en) 2019-08-08
MD3493849T2 (ro) 2022-04-30
CL2019000229A1 (es) 2019-04-26
MX387853B (es) 2025-03-19
MY199733A (en) 2023-11-21
WO2018025049A1 (en) 2018-02-08
SMT202200109T1 (it) 2022-05-12
ES2907838T3 (es) 2022-04-26
HUE057782T2 (hu) 2022-06-28
AU2017305661A1 (en) 2019-02-14
BR112019002130A2 (pt) 2019-05-14
HRP20220252T1 (hr) 2022-04-29
JP6926192B2 (ja) 2021-08-25
IL264538B2 (en) 2023-02-01
EP3493849B1 (en) 2021-12-01
NZ750271A (en) 2025-07-25
UA125394C2 (uk) 2022-03-02
SG11201900565RA (en) 2019-02-27
SI3493849T1 (sl) 2022-04-29
PH12019500237A1 (en) 2019-10-28
CN109562179A (zh) 2019-04-02
IL264538A (enExample) 2019-03-31
DK3493849T3 (en) 2022-03-07

Similar Documents

Publication Publication Date Title
US11896567B2 (en) Combination composition
BRPI0912607A2 (pt) medicamento consistindo em uso concomitante ou combinação de inibidor de dpp-iv e outro medicamento para o diabete
NZ745778A (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
US20250325503A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
AU2011274652B2 (en) A combination composition comprising ibuprofen and paracetamol
CA3032858C (en) Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity
EP1121110B1 (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
HK40005150B (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
JP2019001830A (ja) 医薬
WO2021205153A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803